Small-molecule chromatin-modifying agents: therapeutic applications (Q37961728)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on April 2010

Language	Label	Description	Also known as
English	Small-molecule chromatin-modifying agents: therapeutic applications	scientific article published on April 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Small-molecule chromatin-modifying agents: therapeutic applications (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

object named as

Antonello Mai

1

0 references

publication date

1 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

307-324

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Epigenetics: a landscape takes shape

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The therapeutic uses of chromatin-modifying agents

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone acetyltransferase inhibitors and preclinical studies

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Cancer treatment of the future: inhibitors of histone methyltransferases

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone acetyl transferases as emerging drug targets.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Chromatin modifications and their function

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Acetylation and chromosomal functions.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone acetylation in chromatin structure and transcription

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Enhanced histone acetylation and transcription: a dynamic perspective

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Functions of site-specific histone acetylation and deacetylation

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Multivalent engagement of chromatin modifications by linked binding modules

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Deacetylase enzymes: biological functions and the use of small-molecule inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Class II histone deacetylases: versatile regulators

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Class IIa histone deacetylases: regulating the regulators

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors: Potential in cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

HDAC family: What are the cancer relevant targets?

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

MEF2: a calcium-dependent regulator of cell division, differentiation and death

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

HDAC6 is a microtubule-associated deacetylase

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylases and cancer

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Crystal structure of a bacterial class 2 histone deacetylase homologue

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Clinical studies of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Epigenetic modifiers: basic understanding and clinical development.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Isoform-selective histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Romidepsin for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Specific activity of class II histone deacetylases in human breast cancer cells

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

HDAC inhibitors: clinical update and mechanism-based potential.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Potent antimalarial activity of histone deacetylase inhibitor analogues.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone Deacetylase Inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Candidaemia in Europe: epidemiology and resistance

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors that target tubulin

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Sirtuins in mammals: insights into their biological function

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Recent progress in the biology and physiology of sirtuins

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

The Sir2 family of protein deacetylases

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Acetylation inactivates the transcriptional repressor BCL6.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Opposing activities protect against age-onset proteotoxicity

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

A century of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Therapeutic role of sirtuins in neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides.

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Paths of convergence: sirtuins in aging and neurodegeneration

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Trans-regulation of histone deacetylase activities through acetylation

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.2217%2FEPI.10.7

21 January 2018

Identifiers

10.2217/EPI.10.7

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

release_itrdk7u6x5ffjhekgh2uy4cw4u

1 reference

https://api.fatcat.wiki/v0/release/itrdk7u6x5ffjhekgh2uy4cw4u

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37961728&oldid=1836529095"